Epidemiology of sarcopenia: prevalence, risk factors, and consequences
As weight decreases, patients typically experience: Reduced joint pain and improved mobility Potential improvements in sleep quality and sleep-disordered breathing (though semaglutide is not FDA-approved to treat sleep apnea) Possible improvements in cardiovascular function and stamina as a result of weight reduction Enhanced ability to engage in physical activity Additionally, improved self-efficacy and mood can contribute to perceived energy increases
Medical Uses, Efficacy, and Patient Safety Click here to listen to this article Share via The FDA approved new peptide medications in 2024 and 2025, including treatments for hypoparathyroidism and Barth syndrome
Safety and efficacy of elobixibat, an ileal bile acid transporter inhibitor, in elderly patients with chronic idiopathic constipation according to administration time: interim analysis of post-marketing surveillance
It is used in skincare because it tends to be more formulation friendly than pure vitamin C (ascorbic acid)
Supports digestive comfort.*